The Pharmacovigilance Research Based on Pharmacogenomics

Abstract

CLC Number:

R915

ZHANG Ya-tong, LIANG Xin, SUN Ying-qi, LI Ke-xin, YANG Li-ping, HU Xin, SUN Chun-hua. The Pharmacovigilance Research Based on Pharmacogenomics[J]. Chinese Journal of Pharmacovigilance, 2010, 7(8): 486-489.

References

[1] Uetrecht J. Idiosyncratic drug reactions: current understanding[J]. Annu. Rev. Pharmacol. Toxicol,2007,47:513-539.
[2] Vogel F,Jager P. The genetic load of a human population due to cytostatic agents[J]. Humangenetic, 1969,7:287-304.
[3] Hetherington S, Hughes A R, Mosteller M,et al.Genetic variations in HLA-B region and hypersensitivity reactions to abacavir[J]. Lancet ,2002,359:1121-1122.
[4] Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir[J].Lancet,2002,359:727-732.
[5] Hughes D A, Vilar F J, Ward C C, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hyperse- nsitivity[J]. Pharmacogenetics,2004,14:335-342.
[6] Hung S I,Chung W H,,Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions[J].Pharmacog-enet Genomics, 2006,16:297-306.
[7] Chung W H, Hung S I, Hong H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome[J]. Nature 2004 ,428(6982):486.
[8] Alfirevic A, Jorgensen A L, Williamson P R, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity[J]. Pharmacogenomics ,2006 ,7: 813-818.
[9] Lonjou C, Thomas L, Borot N, et al.A marker for Stevens Johnson syndrome:ethnicity matters[J].Pharmacogenomics,2006,6:265-268.
[10] Saag M, Balu R, Phillips E,et al. High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity(ABC HSR)[R]. Presented at 4th International AIDS Society Meeting, Sydney, Australia 2007.
[11] Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity[J]. Circulation, 2005,112: 3754-3762.
[12] Mushiroda T, Saito S, Tanaka Y,et al.A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms[J]. J. Hum. Genet,2005,50:442-447.
[13] Makita N, Horie M, Nakamura T,et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation[J].Circulation,2002, 106:1269-1274.
（因版面有限,部分参考文献省略,如有需要,请联系编辑部）

[1]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[2]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[3]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[4]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[5]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[8]	HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia. 535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
[9]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[10]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[11]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[12]	PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
[13]	JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
[14]	WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong. Current applications of artificial intelligence in pharmacovigilance in the USA and implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
[15]	ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia. Thyroid immune-related adverse reactions of immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.